MX2019009945A - Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo. - Google Patents

Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo.

Info

Publication number
MX2019009945A
MX2019009945A MX2019009945A MX2019009945A MX2019009945A MX 2019009945 A MX2019009945 A MX 2019009945A MX 2019009945 A MX2019009945 A MX 2019009945A MX 2019009945 A MX2019009945 A MX 2019009945A MX 2019009945 A MX2019009945 A MX 2019009945A
Authority
MX
Mexico
Prior art keywords
treating
same
cognitive disorders
preventing cognitive
agent
Prior art date
Application number
MX2019009945A
Other languages
English (en)
Inventor
Murakami Takashi
Eguchi Hiroshi
Tanokura Akira
Namiki Naoko
E Baker Jeanne
PARMENTIER BATTEUR Sophie
Marie JABLONSKI Angela
Stephen MALASHOCK Daniel
Mieczkowski Carl
Gopalan, ( Raghu) RAGHUNATHAN
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MX2019009945A publication Critical patent/MX2019009945A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La invención proporciona métodos para usar y composiciones de anticuerpos humanizados que se unen a la proteína tau que está fosforilada en la serina en la posición 413.
MX2019009945A 2017-02-27 2018-02-27 Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo. MX2019009945A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017035594A JP2018139530A (ja) 2017-02-27 2017-02-27 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
PCT/IB2018/000249 WO2018154390A1 (en) 2017-02-27 2018-02-27 Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same

Publications (1)

Publication Number Publication Date
MX2019009945A true MX2019009945A (es) 2019-11-05

Family

ID=62025891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009945A MX2019009945A (es) 2017-02-27 2018-02-27 Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo.

Country Status (26)

Country Link
US (3) US10556950B2 (es)
EP (1) EP3585810A1 (es)
JP (3) JP2018139530A (es)
KR (1) KR20190122674A (es)
CN (2) CN110382528A (es)
AR (2) AR110875A1 (es)
AU (1) AU2018224390A1 (es)
BR (1) BR112019016490A2 (es)
CA (1) CA3052538A1 (es)
CL (2) CL2019002296A1 (es)
CO (1) CO2019008786A2 (es)
CR (1) CR20190363A (es)
DO (1) DOP2019000215A (es)
EA (1) EA201991726A1 (es)
GE (1) GEP20227392B (es)
IL (1) IL267945A (es)
JO (1) JOP20180014A1 (es)
MA (1) MA47608A (es)
MX (1) MX2019009945A (es)
MY (1) MY193821A (es)
NI (1) NI201900086A (es)
PE (1) PE20191614A1 (es)
PH (1) PH12019501929A1 (es)
SG (2) SG10201913419TA (es)
TW (1) TW201843179A (es)
WO (2) WO2018154392A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
JOP20180014A1 (ar) * 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
TW202340244A (zh) 2017-10-16 2023-10-16 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
AU2020325770B2 (en) * 2019-08-06 2022-08-25 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
EP4159860A1 (en) * 2020-06-02 2023-04-05 Teijin Pharma Limited Anti-igf-1 receptor humanized antibody
AU2021297873A1 (en) 2020-06-25 2023-02-09 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587390B2 (ja) 1975-03-11 1983-02-09 ツキシマキカイ カブシキガイシヤ ア−クヨウセツホウホウ
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
JP3587390B2 (ja) 1994-03-17 2004-11-10 タカラバイオ株式会社 リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
US7754497B2 (en) 2003-08-29 2010-07-13 Reverse Proteomics Research Institute Co., Ltd. Method for immobilizing proteins
EP1697741A4 (en) 2003-12-04 2008-02-13 Xencor Inc PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CN103502272B (zh) * 2010-10-07 2016-06-15 Ac免疫有限公司 识别Tau的磷酸化特异抗体
SI2627672T1 (sl) * 2010-10-11 2018-10-30 Biogen International Neuroscience Gmbh Človeška protitelesa anti-tau
MY186066A (en) 2011-12-20 2021-06-18 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
US20150183854A1 (en) 2012-05-31 2015-07-02 Teijin Pharma Limited Therapeutic agent or prophylactic agent for dementia
BR112015003326A2 (pt) * 2012-08-16 2017-07-04 Ipierian Inc métodos de tratamento de uma tauopatia
PT2935326T (pt) 2012-12-21 2020-09-14 Biogen Ma Inc Anticorpos anti-tau humanos
ES2800827T3 (es) 2013-06-10 2021-01-04 Ipierian Inc Procedimientos de tratamiento de una tauopatía
SI3083680T1 (sl) 2013-12-20 2020-06-30 F. Hoffmann-La Roche Ag Humanizirana protitelesa proti beljakovini Tau(pS422) in postopki uporabe
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
US10208120B2 (en) 2014-11-05 2019-02-19 Genentech, Inc. Anti-FGFR2/3 antibodies and methods using same
WO2016112078A2 (en) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
CN107849105B (zh) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
NZ738058A (en) 2015-07-06 2021-07-30 UCB Biopharma SRL Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه

Also Published As

Publication number Publication date
JOP20180014A1 (ar) 2019-01-30
CR20190363A (es) 2019-11-05
KR20190122674A (ko) 2019-10-30
CN110382528A (zh) 2019-10-25
BR112019016490A2 (pt) 2020-04-07
JP2020508666A (ja) 2020-03-26
WO2018154392A1 (en) 2018-08-30
SG10201913419TA (en) 2020-03-30
MY193821A (en) 2022-10-27
CN111320695A (zh) 2020-06-23
JP7165996B2 (ja) 2022-11-07
US10894829B2 (en) 2021-01-19
EA201991726A1 (ru) 2020-01-30
US20180346564A1 (en) 2018-12-06
MA47608A (fr) 2020-01-01
CA3052538A1 (en) 2018-08-30
US11739143B2 (en) 2023-08-29
US20200223916A1 (en) 2020-07-16
EP3585810A1 (en) 2020-01-01
DOP2019000215A (es) 2019-09-30
CN111320695B (zh) 2021-09-03
TW201843179A (zh) 2018-12-16
JP2023002670A (ja) 2023-01-10
PE20191614A1 (es) 2019-11-05
JP2018139530A (ja) 2018-09-13
GEP20227392B (en) 2022-06-27
NI201900086A (es) 2019-10-08
WO2018154390A1 (en) 2018-08-30
SG11201907548PA (en) 2019-09-27
AR110875A1 (es) 2019-05-08
US20210380677A1 (en) 2021-12-09
CL2021002389A1 (es) 2022-04-22
CO2019008786A2 (es) 2019-08-20
US10556950B2 (en) 2020-02-11
IL267945A (en) 2019-09-26
PH12019501929A1 (en) 2020-06-29
AU2018224390A1 (en) 2019-07-11
AR117952A2 (es) 2021-09-08
CL2019002296A1 (es) 2019-11-29

Similar Documents

Publication Publication Date Title
PH12019501929A1 (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MX2018010948A (es) INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS.
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
GEP20207162B (en) Lag-3-binding molecules and methods of use thereof
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
EP3826612A4 (en) NOVEL MONOCLONAL ANTIBODIES SPECIFIC TO CLDN 18.2 AND THEIR METHODS OF USE
EA201790342A1 (ru) Антитела к trem2 и способы их применения
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
JOP20190246A1 (ar) جسم مضاد أحادي النسيلة لـ pd-l1
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
WO2018102594A8 (en) Methods of treating solid tumors with anti-cd200 antibodies
GEP20237484B (en) Antibody variants
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
PH12021550991A1 (en) Monoclonal antibody that specifically binds to cd20
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra
CR20210332A (es) Anticuerpo que se une a vegf y a il-1beta y métodos de utilización